Patent expirations and loss of exclusivity. Revenue that disappears on a date; drives M&A and generic entry.
What to watch: Keytruda, Eliquis, and the 2027–30 cliff. It arrives annual, and the effect typically lasts years.
It sits in tier 4 — Stock and sector specific: Moves one company or one group, not the market. Any factor here becomes tier one if it gets large enough — a bank failure and a pandemic both started as somebody's sector news.
Its neighbourhood
Everything this entry connects to directly. Click any point to follow it.
Sectors it moves most
Also in Corporate fundamentals
- Aggregate earnings and guidance
- Corporate profit margins
- Analyst earnings revisions
- Capital expenditure plans
- Share buybacks
- Dividends and payout policy
- Hyperscaler capex, depreciation, and AI monetisation
- Healthcare cost inflation
- Hyperscaler cloud growth and backlog
- Software seat counts and net revenue retention
- App downloads, time spent, and ad load
- Advertising spend and ad prices
- Box office, concert grosses, and ticket prices
- Sports betting handle and casino win
- Senior-living occupancy and care wages
- Death rates and cremation share
- Net equity supply
- Earnings dispersion between AI and non-AI cohorts